SCHEMBL1703567

SCHEMBL1703567

Cc1cccc(NC(=O)Nc2ccc(-c3ccnc4c3c(N)nn4C)cc2)c1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 11/20 0.83
CSF1R P07333 8/20 0.83
BLK P51451 6/20 0.83
KDR P35968 18/20 0.76
FLT3 P36888 12/20 0.76
FLT1 P17948 8/20 0.76
FLT4 P35916 7/20 0.76
LCK P06239 6/20 0.76
LYN P07948 4/20 0.76
ABL1 P00519 3/20 0.76
SRC P12931 2/20 0.76
FYN P06241 1/20 0.76
AURKA O14965 5/20 0.67
AURKB Q96GD4 5/20 0.67
ROCK2 O75116 4/20 0.67
RPS6KB1 P23443 4/20 0.67
PLK4 O00444 3/20 0.67
RPS6KA5 O75582 3/20 0.67
RPS6KA4 O75676 3/20 0.67
PRKD3 O94806 3/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1703132 0.91 CSF1R (1.00) KITCSF1RBLKKDRFLT3
SCHEMBL2821081 0.90 KIT (0.78) KITCSF1RBLKKDRFLT3
SCHEMBL1702825 0.89 KDR (0.78) KITCSF1RBLKKDRFLT3
SCHEMBL1703181 0.89 KDR (0.75) KITCSF1RBLKKDRFLT3
SCHEMBL1703605 0.87 KDR (1.00) KITCSF1RBLKKDRFLT3
SCHEMBL1703245 0.85 KDR (0.78) KITCSF1RBLKKDRFLT3
SCHEMBL1703118 0.85 KIT (0.74) KITCSF1RBLKKDRFLT3
SCHEMBL2818029 0.85 KIT (0.74) KITCSF1RBLKKDRFLT3
SCHEMBL423300 0.85 KDR (1.00) KITCSF1RBLKKDRFLT3
SCHEMBL13135765 0.82 KIT (0.62) KITCSF1RBLKKDRFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 EP claimed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US claimed
US-7812166-B2 Kinase inhibitors ABBOTT LABORATORIES (US) 2010-10-12 US disclosed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178378-A1 Novel kinase inhibitors ABL1, MAP3K19, MAP3K20 KIT 426/4885CSF1R 1265/4885BLK 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.